MarketVIEW Adolescent & STD Vaccines  ·  for order only  ·  2020 edition

Meningococcal ABCWY
Vaccines Forecast

Invasive meningococcal disease can kill up to half of untreated cases within hours and leaves more than 10% of survivors with severe, life-long sequelae, with peak incidence still concentrated in infants and adolescents. Two decades of conjugate ACWY and protein-based serogroup B vaccines have transformed outcomes, and the field has now reached a genuine inflection point: Pfizer's Penbraya and GSK's Penmenvy, the pentavalent ABCWY combination vaccines once tracked on this page as development-stage candidates, are both now approved and ACIP-recommended. This is a comprehensive value/volume forecast of the meningococcal ABCWY opportunity across all age groups, drawing on VacZine Analytics' long standing, independent authority in adolescent vaccine markets.

Up to 50% Fatal If Untreated Peak Incidence: Infants & Adolescents 2 Pentavalent ABCWY Vaccines Now Approved US, EU5, LATAM & MENA Forecast to 2038
Product catalogue
VAMV009
For order only, 2020 edition

Format
Executive presentation + Excel model
Coverage
US, EU5, LATAM, MENA
Indications
All age groups, infant to adult
Forecast horizon
To 2038
Approach
BASE/HI scenario value/volume model
Base edition
2020 edition
Availability
Syndicated / bespoke
50%
Case-fatality rate for invasive
meningococcal disease, left untreated
>10%
Rate of severe, life-long sequelae
among survivors
2,233
Confirmed IMD cases, EU/EEA 2024,
the highest notification rate in 5 years
2
Pentavalent ABCWY vaccines now
approved: Penbraya and Penmenvy
Disease background

A severe, fast-moving disease now rebounding past pre-pandemic levels

This review sets out the clinical severity, serogroup distribution and age-specific epidemiology of Neisseria meningitidis disease, before turning to a post-pandemic rebound that has left both Europe and the United States with their highest case counts in years.

ECDC 2024 & CDC ABCs surveillance data

Pathogen overview - Neisseria meningitidis (N. men)

Neisseria meningitidis (N. men) is a Gram-negative diplococcus and a leading cause of bacterial meningitis and septicaemia worldwide. Invasive meningococcal disease (IMD) progresses with unusual speed, and even with prompt antibiotic treatment can kill within hours of the first symptoms; left untreated, the case-fatality rate can reach 50%. Among survivors, more than 10% are left with severe, life-long sequelae, including limb amputation, hearing loss, neurological damage and skin scarring. Five main serogroups, A, B, C, W and Y, account for the substantial majority of disease in Western countries, with serogroup B historically predominating in young children and serogroups C, W and Y contributing a growing share of adolescent and adult disease.

IMD has a distinctive, bimodal age distribution: incidence peaks first in infants under one year old, when maternal antibody protection wanes and the immune system is still immature, and again in adolescents and young adults, a group whose social mixing patterns and nasopharyngeal carriage rates elevate transmission risk. Historically, serogroup B disease has predominated in children under five, while serogroups C, W and Y have carried disproportionate weight in the adolescent and young-adult peak, precisely the population now targeted by the newest pentavalent combination vaccines.

That long-standing age pattern is being complicated by a genuine post-pandemic rebound with a new demographic signature. Across the EU/EEA, ECDC's most recent annual epidemiological reports recorded 1,895 confirmed IMD cases (200 deaths, notification rate 0.4 per 100,000, the highest since 2020) in 2023, rising further to 2,233 confirmed cases (202 deaths, notification rate 0.5 per 100,000, the highest in five years) in 2024; France, Germany and Spain alone accounted for around 58% of all confirmed EU/EEA cases in 2024, and age-specific notification rates remained highest in infants under one, followed by children aged 1 to 4 and then 15 to 24 year olds, with serogroup B still the leading cause of European IMD overall. In the United States, CDC surveillance shows an even sharper rebound: national case counts have climbed steadily since the pandemic-era lull of 2020/21 and now exceed pre-pandemic levels, with 2023 recording the largest annual total since 2013. Unusually, that US increase has been driven substantially by serogroup Y, and disproportionately by adults aged 30 to 60, Black communities and people living with HIV, a demographic shift away from the historical infant/adolescent-dominated pattern that international forecasters and public health planners are now having to build into their assumptions.

2026 Up to 50% fatal if untreated  |  2,233 EU/EEA cases in 2024, highest in 5 years  |  US cases above pre-pandemic levels, serogroup Y driving an adult-skewed rebound  |  2 pentavalent ABCWY vaccines now approved and ACIP-recommended
Product & competitor landscape

From separate ACWY and B vaccines to two approved pentavalent combinations

The established conjugate ACWY and protein-based serogroup B vaccines remain the backbone of meningococcal prevention, but the field's most consequential recent development is the arrival, and now the approval, of pentavalent ABCWY combination vaccines from both leading manufacturers.

  • GSKApproved
    Menveo MenACWY conjugate
    A long-standing quadrivalent conjugate vaccine covering serogroups A, C, W and Y, approved across infant, toddler, adolescent and adult indications in the US and EU5. Its antigenic components also form the ACWY half of GSK's own pentavalent Penmenvy.
  • SanofiApproved, replacing Menactra
    MenQuadfi MenACWY conjugate
    Sanofi Pasteur discontinued Menactra in 2023, with its last lots expiring that year, transitioning fully to MenQuadfi, a next-generation MenACWY conjugate carrying broader age labelling than its predecessor, including use from age two in the US. In August 2026 the European Commission approved a further label extension permitting use in the EU from six weeks of age, following a June 2026 positive CHMP opinion and the MET58 infant study, opening a genuine infant-programme footprint for MenQuadfi alongside its existing adolescent and adult use.
  • PfizerApproved
    Nimenrix MenACWY conjugate, acquired from GSK
    A quadrivalent conjugate approved from six weeks of age in the EU, used in infant/toddler and adolescent programmes across Malta, the Czech Republic, Greece, the UK, the Netherlands and Austria among others. Its antigenic components form the ACWY half of Pfizer's pentavalent Penbraya.
  • GSKApproved
    Bexsero (4CMenB) MenB, protein-based
    A serogroup B vaccine that made the UK the first country in the world to run a routine infant MenB immunisation programme, from 2015. Its antigenic components form the MenB half of GSK's pentavalent Penmenvy.
  • PfizerApproved
    Trumenba (bivalent rLP2086) MenB, protein-based
    A serogroup B vaccine widely used in US adolescent and young-adult immunisation. Its antigenic components form the MenB half of Pfizer's pentavalent Penbraya, and Trumenba remains the specified second dose when Penbraya is used as the first.
  • PfizerApproved Oct 2023, ACIP-recommended
    Penbraya (MenABCWY) Pentavalent, Trumenba + Nimenrix antigens
    The field's first pentavalent ABCWY vaccine, FDA-approved for ages 10 to 25 in October 2023. ACIP recommends its use, in place of separate MenACWY and MenB administration, for healthy 16 to 23 year olds when shared clinical decision-making favours MenB vaccination, and for individuals aged 10 and over at increased risk of meningococcal disease.
  • GSKApproved Feb 2025, ACIP-recommended
    Penmenvy (MenABCWY) Pentavalent, Bexsero + Menveo antigens
    GSK's own pentavalent ABCWY vaccine, FDA-approved for ages 10 to 25 in February 2025, the direct successor to the GSK3536819A candidate this report previously tracked in development. ACIP voted in April 2025 to recommend Penmenvy as a second pentavalent option alongside Penbraya; the two pentavalent vaccines are not directly interchangeable dose-for-dose.
Field inflection point
2 approved

Pfizer's Penbraya and GSK's Penmenvy have both converted the field's long-tracked pentavalent development programmes into approved, ACIP-recommended products within roughly sixteen months of one another, resolving a competitive question this report had followed for years and materially reshaping the commercial map for adolescent meningococcal prevention in the United States. The UK's JCVI has, to date, not issued an equivalent recommendation on pentavalent ABCWY vaccines, leaving a live market access and positioning question for EU5 and other geographies that this report addresses directly, alongside the post-pandemic, serogroup Y-driven rebound in adult disease. The VacZine Analytics model quantifies the commercial opportunity this creates across all age groups and all four modelled regions under multiple pipeline-progression and recommendation scenarios.

Scope of analysis

Six analytical layers - one commercial picture

This is a genuinely comprehensive report spanning disease burden, target product profile design across all age groups, the full R&D competitive landscape and BASE/HI scenario demand forecasting across the US, EU5, LATAM and MENA.

US, EU5, LATAM & MENA demand forecast

Value ($USD)/volume (000s) demand modelling to 2038 across all relevant meningococcal ABCWY indications and age groups.

Competitor & pipeline review

Full review of conjugated and unconjugated ACWY and MenB products, plus both approved pentavalent ABCWY combinations, Penbraya and Penmenvy.

Target product profile, all age groups

Infant, toddler, adolescent and adult segmentation, reflecting the shift toward pentavalent, single-visit protection.

BASE/HI scenario revenue forecasts

Value/volume forecasts to 2038, visualising the commercial impact of differing recommendation, competitive and pricing scenarios.

Disease burden, incl. post-pandemic rebound

Full epidemiology review across serogroups and age groups, updated with the ECDC 2024 report and CDC ABCs serogroup Y rebound data.

Early decision-making support

Designed as an ideal tool to aid early-stage decision making in meningococcal vaccine investment, market entry and access planning.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the indication and geography framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.

Indication / segmentGeographyTarget groupVaccine statusRevenue scenario
Meningococcal ACWY preventionUSAdolescent (11 to 18yrs)Approved (MenQuadfi/Menveo/Nimenrix)Modelled
Meningococcal B preventionEU5Infant (<1yr)Approved (Bexsero)Modelled
Pentavalent ABCWY (MenABCWY)USAdolescent/young adult (10 to 25yrs)Approved (Penbraya & Penmenvy)Modelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll geographiesAll groupsAll scenarios$███m
Full model in the licensed workbook
US, EU5, LATAM & MENA · to 2038 · all age groups and ABCWY indications
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the meningococcal ABCWY vaccine opportunity across all age groups and regions.

  • Executive presentation - disease background, global epidemiology, target product profile and full competitive environment review, over 100 slides
  • MS-Excel BASE/HI scenario forecast model - value ($USD)/volume (000s) demand outputs to 2038 across all age-group indications and regions
  • Four-region coverage - US, EU5, LATAM and MENA modelled separately and together
  • Competitor intelligence - Menveo, MenQuadfi, Nimenrix, Bexsero, Trumenba, Penbraya and Penmenvy, with full pentavalent field-reset context
  • Updated epidemiology module - ECDC 2024 EU/EEA data and CDC ABCs US data, including the serogroup Y-driven post-pandemic rebound
  • Early decision-making support - target product profile and market entrance strategy guidance for meningococcal ABCWY vaccine planning
Target audience

Built for organisations evaluating the meningococcal ABCWY opportunity

Most valuable to teams assessing the meningococcal vaccine market against their own pipeline, BD ambitions or investment thesis, now that the pentavalent ABCWY era has arrived.

Vaccine developers

Positioning, target product profile and commercial feasibility assessment for meningococcal candidates at any stage of development.

Corporate strategy & BD

Validate the size and structure of a market now defined by pentavalent, single-visit protection rather than separate ACWY and MenB dosing.

Investors & analysts

Independent assessment of pipeline risk and commercial upside for due diligence on Pfizer, GSK, Sanofi and future meningococcal entrants.

Public health & immunisation programmes

Demand modelling to support infant, adolescent and catch-up immunisation programme planning, including pentavalent adoption scenarios.

Researchers & academia

Comprehensive epidemiology and R&D landscape for grant, translational and adolescent vaccine planning purposes.

Market access & policy

Pricing benchmarks and access-pathway assumptions, including the live ACIP/JCVI divergence on pentavalent ABCWY recommendations.

About this analysis · VAMV009

VacZine Analytics has long standing expertise in adolescent diseases, positioning us to track the meningococcal ABCWY vaccine opportunity through both its conjugate-era foundations and its arrival at a genuine pentavalent inflection point. This is a comprehensive analysis spanning all age-group indications across the US, EU5, LATAM and MENA, and it has been well received by clients across the field for the depth of its target product profile and clinical development review. Few groups have followed this market as closely across two decades of vaccine launches, and that recognised, independent expertise underpins everything in the analysis.

This report was last published in 2020, for order only. A refresh would incorporate current global epidemiology, the ECDC 2024 EU/EEA surveillance report, the CDC ABCs serogroup Y-driven US rebound, and both Pfizer's Penbraya and GSK's Penmenvy, the field's first two pentavalent ABCWY vaccines to reach approval and ACIP recommendation. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV009 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc meningococcal ABCWY vaccine analysis, a briefing call is included on request.